An update on adrenocortical cell lines of human origin.
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
05
05
2022
accepted:
10
06
2022
pubmed:
29
6
2022
medline:
20
8
2022
entrez:
28
6
2022
Statut:
ppublish
Résumé
Adrenocortical carcinoma (ACC) is a rare, heterogenous and highly malignant disease. Management of ACC is dependent on disease stage with complete surgical resection as the only potentially curative option. However, advanced, un-resectable, metastatic stages and also recurrences often require systemic treatments, which are unfortunately nowadays still unsatisfactory. The scarcity of preclinical models reflecting patient heterogeneities and furthermore drug-resistant phenotypes, has hampered the progress and development of new therapies in recent years. In this review, we provide an overview on the classical models and substantial progress which has been made over the last years in context of this aggressive disease.
Identifiants
pubmed: 35764904
doi: 10.1007/s12020-022-03112-w
pii: 10.1007/s12020-022-03112-w
pmc: PMC9385758
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
432-437Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s).
Références
B. Kiesewetter et al. Management of adrenocortical carcinoma: are we making progress? Ther. Adv. Med. Oncol. 13, 17588359211038409 (2021)
pubmed: 34484430
pmcid: 8411624
M. Fassnacht et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476–1490 (2020)
pubmed: 32861807
A.F. Gazdar et al. Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res. 50(17), 5488–5496 (1990)
pubmed: 2386954
A. Dierks et al. Identification of adrenal genes regulated in a potassium-dependent manner. J. Mol. Endocrinol. 45(4), 193–206 (2010)
pubmed: 20647392
K.E.M. Ahmed et al. LC-MS/MS based profiling and dynamic modelling of the steroidogenesis pathway in adrenocarcinoma H295R cells. Toxicol. Vitr. 52, 332–341 (2018)
M. Kurlbaum et al. Steroidogenesis in the NCI-H295 Cell Line Model is strongly affected by culture conditions and substrain. Exp. Clin. Endocrinol. Diabetes 128(10), 672–680 (2020)
pubmed: 32349159
K. Nanba, A.R. Blinder, W.E. Rainey, Primary cultures and cell lines for in vitro modeling of the human adrenal cortex. Tohoku J. Exp. Med. 253(4), 217–232 (2021)
pubmed: 33840647
J. Parmar, R.E. Key, W.E. Rainey, Development of an adrenocorticotropin-responsive human adrenocortical carcinoma cell line. J. Clin. Endocrinol. Metab. 93(11), 4542–4546 (2008)
pubmed: 18713819
pmcid: 2582572
T. Wang, W.E. Rainey, Human adrenocortical carcinoma cell lines. Mol. Cell Endocrinol. 351(1), 58–65 (2012)
pubmed: 21924324
C. Hantel et al. Targeting heterogeneity of adrenocortical carcinoma: evaluation and extension of preclinical tumor models to improve clinical translation. Oncotarget 7(48), 79292–79304 (2016)
pubmed: 27764813
pmcid: 5346714
M. Reincke et al. p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 78(3), 790–794 (1994)
pubmed: 8126158
E.M. Pinto, K. Kiseljak-Vassiliades, C. Hantel, Contemporary preclinical human models of adrenocortical carcinoma. Curr. Opin. Endocr. Metab. Res. 8, 139–144 (2019)
pubmed: 32550272
pmcid: 7299197
S.B.C. Sigala, D. Penton, A. Abate, M. Peitzsch, D. Cosentini, G.A.M. Tiberio, S.R. Bornstein, A. Berruti, C. Hantel, A comprehensive investigation of steroidogenic signaling in classical and new experimental cell models of adrenocortical carcinoma. Cells, 2022. 11
F. Tissier et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 65(17), 7622–7627 (2005)
pubmed: 16140927
N.G. Nicolson, R. Korah, T. Carling, Adrenocortical cancer cell line mutational profile reveals aggressive genetic background. J. Mol. Endocrinol. 62(4), 179–186 (2019)
pubmed: 30870809
A. Morin et al. Establishment of a mouse xenograft model of metastatic adrenocortical carcinoma. Oncotarget 8(31), 51050–51057 (2017)
pubmed: 28881628
pmcid: 5584229
C. Hantel, F. Beuschlein, Xenograft models for adrenocortical carcinoma. Mol. Cell Endocrinol. 421, 28–33 (2016)
pubmed: 26033247
M. Doghman et al. Integrative analysis of SF-1 transcription factor dosage impact on genome-wide binding and gene expression regulation. Nucleic Acids Res. 41(19), 8896–8907 (2013)
pubmed: 23907384
pmcid: 3799431
M. Doghman et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol. 21(12), 2968–2987 (2007)
pubmed: 17761949
A. Logie et al. Establishment and characterization of a human adrenocortical carcinoma xenograft model. Endocrinology 141(9), 3165–3171 (2000)
pubmed: 10965887
T.C. Brown et al. Insulin-like growth factor and SLC12A7 dysregulation: a novel signaling hallmark of non-functional adrenocortical carcinoma. J. Am. Coll. Surg. 229(3), 305–315 (2019)
pubmed: 31034883
C. Hantel et al. Liposomal doxorubicin-based treatment in a preclinical model of adrenocortical carcinoma. J. Endocrinol. 213(2), 155–161 (2012)
pubmed: 22407999
F. Beuschlein et al. IGF1-R inhibition and liposomal doxorubicin: progress in preclinical evaluation for the treatment of adrenocortical carcinoma. Mol. Cell Endocrinol. 428, 82–88 (2016)
pubmed: 26994514
S. Sbiera et al. Mitotane Inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells. Endocrinology. 156(11), 3895–3908 (2015)
pubmed: 26305886
C. Hantel et al. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Endocr. Relat. Cancer 21(3), 383–394 (2014)
pubmed: 24532475
S. Jung et al. Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. Endocr. Relat. Cancer 23(10), 825–837 (2016)
pubmed: 27550961
A. Hasanovic et al. Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinoma in vitro and in vivo. Int J. Cancer 143(1), 199–211 (2018)
pubmed: 29411361
C. Siebert et al. Heat shock protein 90 as a prognostic marker and therapeutic target for adrenocortical carcinoma. Front Endocrinol. (Lausanne) 10, 487 (2019)
R. Liang et al. Targeted gene expression profile reveals CDK4 as therapeutic target for selected patients with adrenocortical carcinoma. Front Endocrinol. (Lausanne) 11, 219 (2020)
M. Fragni et al. In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures(). Mol. Cell Endocrinol. 498, 110585 (2019)
pubmed: 31536779
K.M. Warde et al. Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC. Endocr. Relat. Cancer 27(6), 361–373 (2020)
pubmed: 32276262
A. Abate et al. Cytotoxic effect of trabectedin in human adrenocortical carcinoma cell lines and primary cells. Cancers (Basel) 12(4), (2020)
C. Bothou et al. Novel insights into the molecular regulation of ribonucleotide reductase in adrenocortical carcinoma treatment. Cancers (Basel) 13(16), (2021)
G. Cantini et al. Stimulated expression of CXCL12 in adrenocortical carcinoma by the PPARgamma ligand rosiglitazone impairs cancer progression. J Pers. Med. 11(11), (2021)
E. Rossini et al. Cytotoxic effect of progesterone, tamoxifen and their combination in experimental cell models of human adrenocortical cancer. Front Endocrinol. (Lausanne) 12, 669426 (2021)
A. Abate et al. Ribociclib cytotoxicity alone or combined with progesterone and/or mitotane in in vitro adrenocortical carcinoma cells. Endocrinology (2021)
K. Warde et al. Investigating the role of cholesterol and lipid trafficking in mitotane resistance in adrenocortical carcinoma. J. Endocr. Soc. 5(Supplement_1), A70–A70 (2021)
pmcid: 8089352
K.K. Rasiah et al. HSD17B4 overexpression, an independent biomarker of poor patient outcome in prostate cancer. Mol. Cell Endocrinol. 301(1–2), 89–96 (2009)
pubmed: 19100308
H.K. Ko et al. Loss of an androgen-inactivating and isoform-specific HSD17B4 splice form enables emergence of castration-resistant prostate cancer. Cell Rep. 22(3), 809–819 (2018)
pubmed: 29346776
pmcid: 5798464
M. Barnard et al. The role of adrenal derived androgens in castration resistant prostate cancer. J. Steroid Biochem Mol. Biol. 197, 105506 (2020)
pubmed: 31672619
K. Kiseljak-Vassiliades et al. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr. Relat. Cancer 25(4), 437–451 (2018)
pubmed: 29371329
pmcid: 5831504
S. Grisanti et al. Molecular genotyping of adrenocortical carcinoma: a systematic analysis of published literature 2019-2021. Curr. Opin. Oncol. 34(1), 19–28 (2022)
pubmed: 34669649
I. Weigand et al. Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death Dis. 11(3), 192 (2020)
pubmed: 32184394
pmcid: 7078189
K. Kiseljak-Vassiliades et al. Elucidating the role of the maternal Embryonic Leucine Zipper Kinase in Adrenocortical Carcinoma. Endocrinology 159(7), 2532–2544 (2018)
pubmed: 29790920
pmcid: 6669820
A. Kar et al. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocr. Relat. Cancer 26(10), 765–778 (2019)
pubmed: 31325906
pmcid: 6938568
A.G. Maria et al. Inhibition of Aurora kinase A activity enhances the antitumor response of beta-catenin blockade in human adrenocortical cancer cells. Mol. Cell Endocrinol. 528, 111243 (2021)
pubmed: 33716050
pmcid: 8297658
J. Lang et al. Development of an Adrenocortical Cancer Humanized Mouse Model to characterize anti-PD1 effects on tumor microenvironment. J. Clin. Endocrinol. Metab. 105(1), (2020)
L.S. Landwehr et al. A novel patient-derived cell line of adrenocortical carcinoma shows a pathogenic role of germline MUTYH mutation and high tumour mutational burden. Eur. J. Endocrinol. 184(6), 823–835 (2021)
pubmed: 33830941
G.A. Ueland et al. Diagnostic testing of autonomous cortisol secretion in adrenal incidentalomas. Endocr. Connect 9(10), 963–970 (2020)
pubmed: 33032259
pmcid: 7576642
M. Fragni et al. In vitro antitumor activity of progesterone in human adrenocortical carcinoma. Endocrine 63(3), 592–601 (2019)
pubmed: 30367443
C. Fiorentini et al. Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study. J. Clin. Endocrinol. Metab. 101(12), 4594–4602 (2016)
pubmed: 27626976
S. Bornstein et al. Innovative multidimensional models in a high-throughput-format for different cell types of endocrine origin. p. 2022.01.10.475686 (2022)
American Type Culture Collection Standards Development Organization Workgroup ASN-0002, Cell line misidentification: the beginning of the end. Nat. Rev. Cancer 10(6), 441–448 (2010)
L. Cerquetti et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocr. Relat. Cancer 15(2), 623–634 (2008)
pubmed: 18509009